2020年12月16日-18日,由Informa Markets和中國醫(yī)藥保健品進出口商會主辦、上海博華國際展覽有限公司協辦的“第二十屆世界制藥原料中國展”攜手“第十五屆世界制藥機械、包裝設備與材料中國展”于上海新國際博覽中心隆重舉行。制藥在線作為CPhI & P-MEC China 展會官方線上B2B平臺深度參與了這場制藥工業(yè)盛會,通過現場采訪十余位制藥行業(yè)資深專家學者傳遞行業(yè)之聲,展望中國制藥的創(chuàng)新發(fā)展趨勢。
本次展會,制藥在線很榮幸采訪到億騰景昂藥業(yè)首席技術官Deepak Hegde,探討如下話題:
1、Do you think there will be a change on the Drug R&D directions in a post-pandemic future? What are the main trends for drug discovery/drug manufacturing in the future 5-10 years?
2、Which pharmaceutical field will the continuous flow manufacturing be largely applied? Is there a possiblity for the technology to be widely used in the future? What's the applying situation in western countries? What are the main obstacles for transfering from scale batches to continuous flow?
3、What are the challenges do you think the Chinese pharmaceutical companies face to produce quality generics which meet the international standard? What are the key points for the Chinese pharma enterprise to succeed in win the global market?/What quality do you think a good MAH should have?
4、What can the Chinese pharmaceutical companies learn from the experience of the western countires on CMC in development of chemical drugs and bio-logical drugs? How can we avoid receiving an FDA warning letter?
5、Do you think the pharmaceutical manufacturers in western countries are more likely to accept new thechnologies and ideas? What's the reason of that? What should the pharmaceutical companies do to embrace and adapt to the drug manufacturing in the new ages? What do you expect that the Chinese pharmaceutical to be in the future?
合作咨詢
肖女士 021-33392297 Kelly.Xiao@imsinoexpo.com